Overview of Tanzeum

Tanzeum is the trade name for the prescription-only injectable medication containing the active substance Albiglutide, which was clinically recognized for its use in adults to improve glycemic control in Type 2 diabetes mellitus. The product belongs to a sophisticated class of therapeutics that mimic the action of natural gut hormones and is administered via subcutaneous injection as a reconstituted powder solution.

Quick Facts	Description
Active Ingredient	Albiglutide
Form	Lyophilized powder for subcutaneous injection
Pharmacological Class	GLP-1 receptor agonist (Incretin Mimetic)
Common Use	Improving glycemic control in Type 2 diabetes
Origin	Recombinant fusion protein

Albiglutide: Definition and Classification

The active ingredient, Albiglutide, is classified as a Glucagon-like peptide-1 (GLP-1) receptor agonist (incretin mimetic). Pharmacological studies confirm that this means the drug directly stimulates the GLP-1 receptors, replicating the physiological effects of the naturally occurring hormone. Albiglutide's purpose is defined as an antidiabetic agent, serving as a non-insulin option for managing chronic blood sugar conditions.

Composition, Origin, and Dosage Form Differentiation

Albiglutide is a recombinant fusion protein, a biologically engineered substance created using advanced biotechnology. The unique composition, consisting of a modified GLP-1 dimer sequence genetically fused to a fragment of human albumin, represents its primary differentiating factor. This structural fusion grants Albiglutide an extended half-life, a key property allowing the medicine, which is supplied as a lyophilized powder for subcutaneous injection, to be administered on a simplified once-weekly schedule.

Regulatory References

NIH Drug Information

What side effects are possible with Tanzeum?

Possible Side Effects and Safety Information

Tanzeum (albiglutide) is a prescription medication for adults with type 2 diabetes and may cause side effects. Patients should be aware of the serious risks and common adverse reactions associated with this drug.

Warnings and Precautions

Thyroid C-Cell Tumors: Tanzeum carries a Boxed Warning regarding the risk of thyroid C-cell tumors. Other medications in this class (GLP-1 receptor agonists) have caused these tumors, including medullary thyroid carcinoma (MTC), in rodent studies. It is unknown if Tanzeum increases this risk in humans. The drug is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pancreatitis: Acute pancreatitis has been reported. Symptoms include persistent, severe abdominal pain, which may or may not radiate to the back and may be accompanied by vomiting. If suspected, Tanzeum must be promptly discontinued and should not be restarted if pancreatitis is confirmed.
Hypoglycemia: The risk of low blood sugar is low when Tanzeum is used alone, but it increases significantly when combined with an insulin secretagogue (like a sulfonylurea) or insulin. A dose reduction of the concomitant medication may be necessary to prevent hypoglycemia.
Hypersensitivity: Serious hypersensitivity reactions, including angioedema (swelling of the face, lips, or tongue), have occurred. Patients should seek immediate medical attention if a severe allergic reaction is suspected.

Common Side Effects

The most commonly reported side effects (occurring in 5% or more of patients) in clinical trials included:

Adverse Reaction	Tanzeum (%)	Placebo (%)
Upper respiratory tract infection	14.2	13.0
Diarrhea	13.1	10.5
Nausea	11.1	9.6
Injection site reaction	10.5	2.1

Other common side effects include cough, back pain, joint pain (arthralgia), sinusitis, and influenza (flu) symptoms. Gastrointestinal side effects, such as diarrhea and nausea, were generally mild to moderate and tended to decrease over time.

Overdose and Emergency Response

The official regulatory documentation for Albiglutide (Tanzeum) defines the manifestations of an overdose as an expected, excessive pharmacological effect, which mandates immediate clinical attention.

Overdose Scope

The primary clinical consequences documented for an overdose involve the metabolic system and the gastrointestinal system. Specifically, an overdose results in hypoglycemia, which is an excessive reduction of blood glucose levels. Furthermore, patients may experience severe gastrointestinal adverse reactions, notably severe nausea and severe vomiting. These severe gastrointestinal symptoms carry a risk of dehydration, which regulatory documents note can lead to a risk of worsening renal function, particularly in patients with pre-existing renal impairment.

Overdose Classifications

The potential for severe hypoglycemia is classified as the most critical metabolic risk requiring urgent management. Management of an overdose is directed entirely toward being symptomatic and supportive, as official labeling confirms that no specific antidote is known to reverse the drug's effects. A key consideration is the extended half-life of Albiglutide, which is why regulatory guidance requires that patients undergo prolonged observation and continuous glucose monitoring under hospital care until all overdose effects have fully resolved. In all suspected cases, the official instruction is to seek immediate medical attention.

Therapeutic Uses of Tanzeum

What Tanzeum Treats: Main Uses and Benefits

Tanzeum (Albiglutide) is a medication primarily indicated for adults with Type 2 Diabetes Mellitus. This treatment is applied across domains where additional symptomatic support is needed, with key uses including supporting management of elevated blood glucose indicators, addressing established cardiovascular risk, and supporting broader metabolic goals like weight stability.

The medication is commonly used to help with chronic hyperglycemia in conditions where symptoms may intensify temporarily and markers like HbA1c and Fasting Plasma Glucose remain inadequately controlled. The therapeutic goal is to support the management of glycemic control, which contributes to easing the overall symptom load by contributing to the management of long-term risk of severe diabetes-related damage.

For patients with established atherosclerotic cardiovascular disease, Tanzeum is relevant for managing elevated metabolic risk factors by assisting in addressing the risk of serious events like heart attack or stroke.

Quick Fact: Relief for Systemic Imbalance
Contributes to the management of long-term risk associated with chronic high blood sugar and assists with maintaining functional stability in high-risk patients.

Eligibility and Restrictions for Use

Tanzeum (albiglutide) is officially indicated for use only in adults with Type 2 Diabetes Mellitus. Eligibility is strictly governed by authoritative regulatory documents which establish absolute prohibitions and specific restrictions based on patient history and clinical conditions.

Contraindicated Populations

The medicine is strictly contraindicated (must not be used) in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also prohibited for patients with a documented prior serious hypersensitivity reaction to albiglutide or any component of the product.

Eligibility Restrictions and Limitations

Type 1 Diabetes and DKA: Tanzeum is not indicated for the treatment of Type 1 Diabetes Mellitus or Diabetic Ketoacidosis; it is not a substitute for insulin in these acute settings.
Pediatric Use: Safety and effectiveness have not been established in pediatric patients (under 18 years of age), making its use not recommended in this age group.
Gastrointestinal Disease: Use is not recommended in patients with pre-existing severe gastrointestinal disease, including severe gastroparesis, as clinical data in this population is lacking.
Pancreatitis: Consideration should be given to alternative antidiabetic therapies in patients with a history of pancreatitis.
Renal/Hepatic Impairment: No dose adjustment is recommended for mild, moderate, or severe renal impairment or for hepatic impairment. However, caution is advised and renal function should be monitored if severe gastrointestinal symptoms occur in patients with renal impairment.
Pregnancy/Lactation: Use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. For lactation, a decision to discontinue nursing or discontinue the drug is required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tanzeum (Albiglutide) has officially documented interaction patterns primarily concerning blood glucose control and the absorption of other medicines.

A significant pharmacodynamic interaction exists with other glucose-lowering agents. Co-administration with Insulin or Insulin Secretagogues (such as sulfonylureas) is associated with an officially documented, increased risk of hypoglycemia (low blood sugar). Furthermore, the regulatory label notes that when Tanzeum is administered with Insulin, they must be given as separate injections and should not be placed adjacent to one another in the same body region.

Due to its effect on the digestive system, a pharmacokinetic interaction is documented for oral medications. Albiglutide causes delayed gastric emptying, an effect which may alter the rate and extent of absorption of concurrently administered oral medicines. This was demonstrated in studies with the model drug Simvastatin, where changes in plasma exposure (AUC and Cmax) for the drug and its active metabolite were observed.

An interaction with non-medicinal substances is also documented: co-administration with alcohol is formally associated with a potential risk of severe low blood sugar. Finally, use of the product is strictly restricted, or contraindicated, for any patient with a prior serious hypersensitivity reaction to Albiglutide or any of its components.

Mechanism of Action

Incretin System Activation and Structural Durability

Tanzeum (Albiglutide) functions as an agonist on the Glucagon-Like Peptide-1 (GLP-1) receptor. The drug is a structurally modified fusion protein engineered to be resistant to degradation by the enzyme Dipeptidyl Peptidase-4 (DPP-4). This structural resistance ensures sustained receptor occupancy and prolonged duration of the pathway modulation.

Glucose-Dependent Pancreatic Regulation

Activation of the GLP-1 receptor modulates hormonal output from the pancreas. The mechanism enhances insulin release from β-cells that is strictly glucose-dependent, while simultaneously suppressing the secretion of glucagon from α-cells. This dual action contributes to the regulation of glucose homeostasis pathways.

Gastrointestinal Motility Modulation

A third component involves modulation of gastrointestinal function. The drug engages receptors that specifically lead to the slowing of gastric emptying. This action controls the rate at which nutrients exit the stomach and enter the bloodstream, resulting in a reduced rate of glucose absorption.

Dosage and Administration Information

Administration Overview

Tanzeum is administered as a subcutaneous injection. This means the medication is delivered into the fatty tissue layer just beneath the skin. Common injection sites include the abdomen, thigh, or the back of the upper arm. It is important to rotate the specific injection site within the chosen area with each dose to reduce the risk of skin irritation or tissue changes.

Preparation and Timing

The medication is typically provided in a pen device that requires a reconstitution process before use. This process involves mixing the powder medication with a pre-filled liquid diluent contained within the device. Once the medication is mixed, the solution should be clear and colorless to pale yellow. If the solution is cloudy or contains visible particles, it should not be used.

Tanzeum can be administered at any time of day, regardless of the timing of meals. The injection should be performed immediately after the medication has been reconstituted and prepared.

Handling and Storage

Prior to its first use, the medication should be kept in its original packaging. If the medication has been refrigerated, it is often recommended to allow the pen to sit at room temperature for a brief period before starting the mixing process to ensure the liquid flows easily.

Used needles and injection devices should be disposed of in a puncture-resistant container specifically designed for sharps. Proper disposal ensures that the components are handled safely after the medication has been delivered.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical data for Tanzeum (albiglutide) primarily stem from the HARMONY program, a series of randomized, double-blind, and open-label Phase 3 trials that evaluated the compound in adults with type 2 diabetes. These studies assessed the compound's effect on blood glucose control over periods of up to three years.

Efficacy in Glycemic Control

Studies in the HARMONY program explored the use of albiglutide as a monotherapy and in combination with other anti-diabetic medications, including metformin, sulfonylureas, and insulin glargine. The primary measure of efficacy was the change in glycated hemoglobin (HbA1c) from baseline. Across the key trials, albiglutide was observed to be associated with statistically significant reductions in HbA1c levels compared to placebo, and demonstrated non-inferiority to certain active comparators in some studies.

Cardiovascular Outcomes (HARMONY Outcomes Trial)

One significant component, the HARMONY Outcomes trial, was a long-term, randomized, placebo-controlled study involving over 9,400 patients with type 2 diabetes and established cardiovascular disease. This study investigated the effect of albiglutide on Major Adverse Cardiovascular Events (MACE), a composite endpoint defined as cardiovascular death, non-fatal myocardial infarction (MI), or non-fatal stroke. Findings indicated that the addition of albiglutide to standard care was associated with a reduction in the risk of MACE compared to placebo. Analysis suggested this reduction was primarily driven by a decrease in MI events.

Primary Outcome	Finding vs. Placebo (HARMONY Outcomes)
Major Adverse Cardiovascular Events (MACE)	Associated with a statistically significant reduction in risk
Cardiovascular Death	No significant difference observed

Safety and Tolerability Profile

Overall, the most common reported adverse events were gastrointestinal complaints (such as nausea and diarrhea) and injection site reactions. The observed safety and tolerability profile in the long-term studies was generally consistent with findings from the initial one-year assessment periods.

Frequently Asked Questions (FAQ)

Common questions about Tanzeum (FAQ)

Q: Is Tanzeum used for weight loss, or only for diabetes?

A: According to the official product information, the primary indication for Tanzeum is to improve blood sugar control in adults with type 2 diabetes mellitus. It is not officially indicated or approved as a weight-loss medicine. While some patients experienced weight changes in clinical trials, this is not the drug's approved purpose.

Q: Are there any major diet restrictions when using Tanzeum?

A: Regulatory documents state that the injection can be administered at any time of day, regardless of when you eat. However, it is important that patients continue to follow the medical nutrition therapy and dietary guidance associated with their diabetes management.

Q: What is the purpose of the injection pen device used for Tanzeum?

A: The pen device is specifically designed to correctly mix the lyophilized powder within the pen reservoir and deliver the reconstituted medicine. The system is designed to facilitate the delivery of the prescribed dose via a single subcutaneous injection into the prescribed areas, such as the abdomen, thigh, or upper arm.

Q: Are there specific symptoms that require immediate medical attention while on Tanzeum?

A: Yes, official warnings advise seeking immediate medical help if you experience signs of a serious allergic reaction, such as swelling of the face, lips, or throat, or difficulty breathing. Patients are advised to seek prompt medical attention if symptoms suggestive of acute pancreatitis occur, like severe and persistent abdominal pain that may spread to the back.

Q: If I travel, how should I handle my Tanzeum pen?

A: When traveling, official patient instructions advise carrying a recent prescription and medical history with you. Consultation with a healthcare provider is recommended when crossing time zones to ensure the once-weekly dosing schedule remains consistent.

Q: Is Tanzeum a hormone?

A: Tanzeum (albiglutide) is not a natural hormone in the body, but it is a complex, bioengineered recombinant fusion protein. It is classified as a GLP-1 receptor agonist, meaning it works by mimicking the action of the natural gut hormone Glucagon-Like Peptide-1 (GLP-1) to help regulate blood sugar.

Q: Can I take Tanzeum with high blood pressure medication?

A: The official label does not specifically address high blood pressure medications (antihypertensives). Discussion of all prescription medicines, including those for high blood pressure, with a healthcare provider is necessary due to the drug's potential to alter the absorption rate of oral drugs.

Q: Does Tanzeum interact with common over-the-counter pain relievers?

A: The product label does not specifically mention common nonprescription pain relievers. Since the medicine is known to delay the movement of food out of the stomach, the absorption rate of all oral medications may be affected. Reviewing all nonprescription drugs and supplements with a healthcare provider is necessary.

Q: How long does it take for Tanzeum to start having an effect?

A: Official pharmacological data indicates that the drug reaches its peak concentration in the bloodstream typically between three and five days after administration. This pharmacokinetic property is what enables the medicine to be effective with a once-weekly dosing schedule.

Q: What happens if I stop using Tanzeum suddenly?

A: Any sudden cessation of Tanzeum use requires prior consultation with a healthcare provider. If the medicine is discontinued, the physician must be consulted immediately to ensure a smooth transition to an alternative therapy to prevent a loss of glycemic control.

Q: Is Tanzeum safe for older adults (seniors)?

A: Official information regarding geriatric use (patients 65 and older) indicates that clinical studies have not identified age-specific problems that would limit the usefulness of this medicine. Therefore, no dosage adjustment is recommended based on age alone.

Q: Is Tanzeum known to cause vision problems?

A: Official safety documents list blurred vision as a potential sign or symptom of hypoglycemia (low blood sugar). This risk is increased when Tanzeum is used in combination with other blood sugar-lowering agents, such as insulin or a sulfonylurea.

Q: What common foods or supplements should be avoided with Tanzeum?

A: The official product information specifies a warning only for alcohol consumption, which is formally associated with a potential risk of severe low blood sugar. No other specific common foods or supplements are listed for avoidance in the regulatory label.

Q: Why did the manufacturer stop making Tanzeum?

A: Official discontinuation notices confirm that the manufacturer voluntarily stopped making the medicine for commercial reasons. This decision was based on factors such as declining sales and limited prescribing, and was not related to any new safety concerns about the product itself.

Q: Is Tanzeum still available by prescription in the US or other countries?

A: No. The medicine was voluntarily discontinued by the manufacturer for commercial reasons and is no longer commercially available in the US or in the European Union. Patients previously using this medication were advised to transition to alternative diabetes therapies.

Q: Can Tanzeum affect my liver function?

A: The official label does not cite a specific risk of liver injury, and no dose adjustment is officially recommended for patients with hepatic impairment (liver problems). However, patients with pre-existing liver disease are advised to have their condition reviewed by a healthcare provider before use.

Q: Is Tanzeum known to cause headaches or dizziness?

A: Headache and dizziness or light-headedness are listed in official safety documents as potential signs or symptoms of hypoglycemia (low blood sugar). This side effect is more likely to occur when the medicine is used along with insulin or an insulin secretagogue.

Q: Can men and women use Tanzeum equally?

A: Pharmacokinetic studies officially reviewed by regulators determined that gender has no clinically relevant effect on the action or effectiveness of the drug. This indicates equal suitability for use in both men and women.

Q: How does Tanzeum interact with birth control pills?

A: Due to the medicine's action of delaying the speed at which the stomach empties, it may alter the rate and extent of absorption of concurrently administered oral medicines, which includes oral hormonal contraceptives. Discussion of oral hormonal contraceptives with a healthcare provider is recommended for patients using this medicine.

How should Tanzeum be stored and disposed of?

Storage and Disposal Requirements for Tanzeum

Storage Scope	Regulatory Condition
Temperature Requirements (Unused Pen)	Store refrigerated at 2 C to 8 C (36 F to 46 F). Can be stored at room temperature (le 30 C or 86 F) for a maximum of four weeks.
Stability after Reconstitution	The mixed solution must be used within 8 hours of mixing the powder and liquid.
Protection and Handling	Do not freeze the pen; discard if it has been frozen. Store in the original carton to protect from light. Do not shake the pen during mixing.
Child-Safety	Keep the medication out of the reach of children.
Disposal Instructions	Used pens and needles must be placed immediately into an FDA-cleared sharps disposal container. Unused or expired medicine must be disposed of according to local regulations.

Tanzeum